(REUTERS) Canada’s health regulator is launching a probe into Pfizer’s arthritis drug, Xeljanz, after a trial by the company identified an increased risk of serious heart-related issues and cancer in the participants. The trial investigated the long-term safety of Xeljanz at two doses in patients with rheumatoid arthritis, who... Read more